A Potential Novel Marker for Liver Fibrosis in Nonalcoholic Steatohepatitis: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor Non-interventional Study.
N/A
18 Years
90 Years
18 Years
90 Years
Not Enrolling
Both
Liver Fibrosis
Both
Liver Fibrosis
Trial Information
A Potential Novel Marker for Liver Fibrosis in Nonalcoholic Steatohepatitis: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor Non-interventional Study.
Inclusion Criteria:
1. Signed informed consent.
2. Patient candidate to bariatric surgery.
Exclusion Criteria:
1. Liver biopsy during the last 12 months.
2. The surgeon consider liver biopsy as a special dander in a specific patient.
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Cross-Sectional
Principal Investigator
Osamah Hussein, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Ziv Medical Center
Authority:
Israel: Ethics Commission
Study ID:
0022-09 ZIV
NCT ID:
NCT00941902
Start Date:
May 2009
Completion Date:
February 2011
Related Keywords:
- Liver Fibrosis
- human asialoglycoprotein receptor (ASGPR)
- hepatocytes
- bariatric surgery
- Fibrosis
- Liver Cirrhosis
Name | Location |
|---|
